Zheng Quan Shi Bao Wang·2025-07-01 10:22Core Viewpoint - The hepatitis concept sector has seen a 2.30% increase, ranking 10th among concept sectors, with significant gains from stocks like Guizhou Bailing, Weiming Pharmaceutical, and Kexing Pharmaceutical [1]. Group 1: Sector Performance - The hepatitis concept sector had 116 stocks rising, with Guizhou Bailing, Weiming Pharmaceutical, and *ST Sailong hitting the daily limit up [1]. - Notable gainers included Kexing Pharmaceutical, Yipin Hong, and Rejing Biological, which rose by 15.62%, 14.72%, and 11.60% respectively [1]. - The sector's performance was contrasted by declines in stocks like *ST Suwu, *ST Sihuan, and New Industry, which fell by 0.79%, 0.78%, and 0.48% respectively [1]. Group 2: Capital Inflow - The hepatitis concept sector attracted a net inflow of 790 million yuan, with 71 stocks receiving net inflows [1]. - Yipin Hong led the net inflow with 168 million yuan, followed by Guizhou Bailing and Kexing Pharmaceutical with net inflows of 158 million yuan and 97.8 million yuan respectively [1]. - The top three stocks by net inflow rates were Guizhou Bailing at 17.80%, Weiming Pharmaceutical at 16.28%, and Kexing Pharmaceutical at 14.10% [2].